<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------
SCHEDULE 14D-1
(AMENDMENT NO. 1)
TENDER OFFER STATEMENT PURSUANT TO SECTION 14(D)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
SCHEDULE 13D
(AMENDMENT NO. 11)
UNDER THE SECURITIES AND EXCHANGE ACT OF 1934
---------------------
SYSTEMIX, INC.
(Name of Subject Company)
NOVARTIS BIOTECH HOLDING CORP.
AND
NOVARTIS INC.
(Bidder)
COMMON STOCK, $.01 PAR VALUE
(Title of Class of Securities)
871872 10 7
(CUSIP Number of Class of Securities)
---------------------------
ROBERT L. THOMPSON, JR., ESQ.
NOVARTIS BIOTECH HOLDING CORP.
NOVARTIS INC.
C/O NOVARTIS CORPORATION
608 FIFTH AVENUE, 10TH FLOOR
NEW YORK, NEW YORK 10020
(212) 830-2401
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications on Behalf of Bidder)
---------------------------
COPY TO:
DAVID W. HELENIAK, ESQ.
599 LEXINGTON AVENUE
NEW YORK, NEW YORK 10022
TELEPHONE: (212) 848-4000
JANUARY 30, 1997
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
This Amendment No. 1 to the Tender Offer Statement on Schedule
14D-1 and Amendment No. 11 to the Statement on Schedule 13D (this
"Amendment") relates to the offer by Novartis Biotech Holding Corp., a
Delaware corporation ("Purchaser") and an indirect wholly owned subsidiary of
Novartis Inc., a company organized under the laws of Switzerland ("Parent"),
to purchase all outstanding shares of Common Stock, par value $.01 per share
(the "Common Stock"), of SyStemix, Inc. (the "Shares"), a Delaware
corporation, at a price of $19.50 per Share, net to the seller in cash, upon
the terms and subject to the conditions set forth in Purchaser's Offer to
Purchase dated January 17, 1997 (the "Offer to Purchase") and in the related
Letter of Transmittal (which together constitute the "Offer").
ITEM 10. ADDITIONAL INFORMATION.
Item 10(e) is hereby amended and supplemented as follows:
Parent and the other defendants have reached an agreement with
the plaintiffs to settle the consolidated action captioned In Re SyStemix, Inc.
Shareholder Litigation, Consolidated C.A. 15014. If this agreement is accepted
and approved by the Delaware Chancery Court, the case would be dismissed with
prejudice. As a part of such a settlement and dismissal, Parent and the other
defendants would not object to a court award of attorneys' fees and expenses
to counsel for plaintiffs of $385,000 or less.
<PAGE>
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
January 30, 1997
NOVARTIS BIOTECH HOLDING CORP.
By: /s/ ROBERT L. THOMPSON, JR.
-----------------------------------------
Name: Robert L. Thompson, Jr.
Title: Vice President
<PAGE>
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
January 30, 1997
NOVARTIS INC.
By: /s/ ROBERT L. THOMPSON, JR.
-----------------------------------------
Name: Robert L. Thompson, Jr.
Title: Attorney-in-Fact
